A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2018
At a glance
- Drugs Tislelizumab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 22 Jul 2018 According to a BeiGene media release, full results of the trial are expected to be presented at an upcoming medical conference.
- 22 Jul 2018 According to a BeiGene media release, Biologics License Application (BLA) planned to be filed with the China Drug Administration (CDA) in late 2018.
- 22 Jul 2018 Preliminary topline results (N=70) published in the BeiGene Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History